Home›Docetaxel

Docetaxel

Also known as: Beizray

Microtubule Inhibitor

Route: Intravenous

8 interactions on record⛔ Black Box Warning

Docetaxel has 8 known drug interactions based on U.S. FDA drug labeling data. 2 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Ketoconazole, Ritonavir, Aprepitant. Patients taking Docetaxel should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 8
Major: 2
Moderate: 6

Major (2)

Docetaxel + Ketoconazole— Potent CYP3A4 inhibitor that increases docetaxel exposure 2.2-fold when coadministered. Concomitant use should be avoide…
Docetaxel + Ritonavir— Protease inhibitor and potent CYP3A4 inhibitor that may increase docetaxel exposure. Concomitant use should be avoided; …

Moderate (6)

Docetaxel + Aprepitant— Increased docetaxel exposure possible; no dosage adjustment needed but monitor for adverse reactions.
Docetaxel + Epirubicin Hydrochloride— Administration of epirubicin immediately prior to or after docetaxel increases systemic exposure of epirubicin metabolit…
Docetaxel + Fosaprepitant— Increased exposure of chemotherapeutic agent; no dosage adjustment needed but monitor for adverse effects.
Docetaxel + Fosaprepitant Dimeglumine— Increased exposure possible via CYP3A4 inhibition, but no dosage adjustment needed. Monitor for adverse reactions.
Docetaxel + Netupitant And Palonosetron— Chemotherapy agent metabolized by CYP3A4; systemic exposure can increase with AKYNZEO; caution and monitoring advised.
Docetaxel + Thalidomide— Docetaxel causes peripheral neuropathy and concomitant use with thalidomide can cause additive effect; should be used wi…

Docetaxel + Ketoconazole⚠️Major

Potent CYP3A4 inhibitor that increases docetaxel exposure 2.2-fold when coadministered. Concomitant use should be avoided; if unavoidable, dose reduction and close toxicity monitoring required.

Docetaxel + Ritonavir⚠️Major

Protease inhibitor and potent CYP3A4 inhibitor that may increase docetaxel exposure. Concomitant use should be avoided; if unavoidable, dose reduction and close toxicity monitoring required.

Docetaxel + Aprepitant🟡Moderate

Increased docetaxel exposure possible; no dosage adjustment needed but monitor for adverse reactions.

Docetaxel + Epirubicin Hydrochloride🟡Moderate

Administration of epirubicin immediately prior to or after docetaxel increases systemic exposure of epirubicin metabolites. Monitor for additive hematologic and gastrointestinal toxicity.

Docetaxel + Fosaprepitant🟡Moderate

Increased exposure of chemotherapeutic agent; no dosage adjustment needed but monitor for adverse effects.

Docetaxel + Fosaprepitant Dimeglumine🟡Moderate

Increased exposure possible via CYP3A4 inhibition, but no dosage adjustment needed. Monitor for adverse reactions.

Docetaxel + Netupitant And Palonosetron🟡Moderate

Chemotherapy agent metabolized by CYP3A4; systemic exposure can increase with AKYNZEO; caution and monitoring advised.

Docetaxel + Thalidomide🟡Moderate

Docetaxel causes peripheral neuropathy and concomitant use with thalidomide can cause additive effect; should be used with caution.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.